The specifics, since they change the answer: 96.8% · survodutide · WWB.
I am at the decision point and I would rather think it through than improvise.
I would rather spend money on measurement than on redundancy.
What does a sensible plan look like, and what are the decision points?
Put another way, the method matters more than the vial, which is why specifying a method buys you far more than changing suppliers does.
Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.
| Component | Typical share | Counted in purity? | Counted in content? |
|---|---|---|---|
| Target peptide | 88–94 % | Yes, as main peak | Yes |
| Related impurities | 1–3 % | Yes, as other peaks | No |
| Counter-ion (TFA or acetate) | 2–8 % | No | No |
| Residual water | 2–6 % | No | No |
| Bulking agent, if present | 0–40 % | No | No |
Stated carefully, the fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.
Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.
Worth noting that method standardisation is poor in the research-grade space compared to pharmaceutical work, so identical-looking methods can produce different results.
If you are ranking vendors, specify a method and have all samples tested at the same place.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsThe part that matters: read the chromatogram before you read the number, because the number without the trace is not a measurement, it is a claim.
Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.
Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.
The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.
Compare purity within a single laboratory on the same method, never across laboratories.
Put another way, purity is a method-dependent figure, and that is not a limitation of the measurement, it is a property of what the measurement actually answers.
Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.
Buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.
Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.
The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.
edited 20 Jun 2025 by bac_or_bust — added the citation requested in comments
The single most important distinction is between what purity measures — the fraction of detected material that is your target — and what you actually want to know — how much of the material in the vial is your target.
Tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.
The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.
I would be careful about over-reading a single measurement — treat it as a data point, not as ground truth.
If you are ranking vendors, specify a method and have all samples tested at the same place.
Put another way, area percentage is not mass percentage, and conflating the two is the most common misreading of a purity figure.
Column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.
The caveat is that purity without identity is only half an answer — a high purity does not mean the peak is actually what you think it is.
Compare purity within a single laboratory on the same method, never across laboratories.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.